The effects of staurosporine on a selection of protein kinases were investigated with thrombin-stimulated and control human blood platelets. The results demonstrate that staurosporine (1 M) can lead to activation of certain protein kinases in intact platelets and has a general inhibitory effect on the renaturable protein kinases in vitro. New candidates for protein kinases involved in signal transduction are identified.
INTRODUCTION
Protein kinases are involved in signal-transduction processes in human platelets. Activation with physiological stimuli leads to increased phosphorylation of five or six major and many minor proteins [1] . Activation with thrombin leads to rapid breakdown of inositides, followed by transient elevations of intracellular Ca2+ and diacylglycerol (DAG) [2] , which activates protein kinase C (PKC) [3] . Pleckstrin (P 47) and myosin light chain are known substrates for PKC [4, 5] . The myosin light chain is also phosphorylated by the calmodulin-dependent myosin light-chain kinase that is activated by an increase in intracellular Ca2c oncentration [6] . Protein kinases are also involved in platelet inhibition. Membrane glycoprotein Ib and actin-binding protein are phosphorylated by cyclic AMP-dependent protein kinase when platelets are treated with prostaglandin-El, thus inhibiting collagen-induced polymerization of actin [7] . Tyrosine-specific protein kinases are involved in platelet activation. Platelets contain relatively high levels of pp6Oc S7C, the normal cellular homologue of the transforming protein of Rous sarcoma virus, which is a tyrosine kinase [8] . Platelet tyrosine phosphorylation is transiently elevated after thrombin stimulation [9] . The interaction of the platelet membrane glycoprotein lIb/IIIa integrin complex with peptides that inhibit fibrinogen binding affects the phosphorylation of several tyrosine kinase substrates, suggesting their involvement in platelet-aggregation pathways [10] . Phorbol esters or DAG and exogenous Ca2+ ionophores act synergistically to activate platelets, thus simulating the biological effects of thrombin [3] . Staurosporine, a microbial alkaloid with antifungal properties, is widely used as a PKC inhibitor . In vitro PKC is affected at nanomolar concentrations, but other protein kinases are inhibited as well at the same or higher concentrations [15] [16] [17] . However, growing evidence suggests that staurosporine not only has inhibitory effects, but may also cause stimulation in vivo and in intact cells [18] [19] [20] [21] [22] [23] . It does not prevent PKC binding to phospholipids and phorbol esters, but inhibits substrate phosphorylation and autophosphorylation at nanomolar concentrations [15] and appears to interact directly with the catalytic moiety of the enzyme [11] . In platelets it had no effect on formation of phosphatidic acid and inositol phosphates induced by thrombin, but it inhibited the phosphorylation of pleckstrin and myosin light chain [24] . Platelet aggregation induced by collagen or ADP was inhibited by staurosporine [25] . It also had some inhibitory effects on thrombin-induced aggregation of platelets, but shape change and secretion were completely inhibited [26] . After electrophoresis and transfer of the proteins to polyvinylidene difluoride (PVDF) membranes, kinase activity could be restored by renaturation [27] . Some novel renaturable protein kinases have increased activities in vitro after activation of platelets, as previously reported [28] . This increased activity was measured as increased autophosphorylation and also higher phosphorylation of exogenous substrates (e.g. BSA). Renaturation of blotted proteins was used to investigate the influence of staurosporine on the activation and activities of the renaturable and covalently modified protein kinases from human blood platelets.
MATERIALS AND METHODS

Materials and chemicals
Apyrase, BSA (fraction V, and fatty-acid-free fraction V), staurosporine, acid phosphatase (from potatoes) and the prestained molecular-mass markers were from Sigma, St. Louis, MO, U.S.A. Thrombin was from Merck, Zurich. Iloprost was kindly given by Schering A.G., Zurich, Switzerland. Hepes was from Calbiochem, Lucerne, Switzerland. Guanidine hydrochloride was from Fluka, Buchs, Switzerland, and Nonidet P-40 was from Grogg, Berne, Switzerland. [y-32P]ATP (3000 Ci/mmol) was from Amersham International, Amersham, Bucks., U.K. The PVDF membranes (Immobilon-P) were from Millipore, Bedford, MA, U.S.A. Alkaline phosphatase (from calf intestine) was from Boehringer Mannheim, Rotkreuz, Switzerland.
Isolation of human platelets
Buffy coats were obtained from the Swiss Red Cross in Berne (FDA four-bag system) approx. 15 h after collection. Buffy-coat dilution buffer (0.1 vol.) was added to give final concentrations of 10 mM-sodium citrate and 0.15 unit of apyrase/ml, and the suspension was centrifuged at 150 g for 15 min. The platelet-rich plasma was removed and acidified to pH 6.5 with 150 mM-citric acid, iloprost was added to final concentration of 1 ng/ml, and centrifugation at 500 g for 15 min pelleted the platelets. They were washed with 2 x 100 vol. of 137 mM-NaCl, containing 11 mM-glucose, 11 mM-sodium citrate, 0.2 unit of apyrase/ml and 0.25 % BSA (fatty-acid-free), pH 6.5, and then resuspended in 137 mM-NaCl/2 mM-KCl/ 1 mM-MgCl2/ 1 mM-CaCl2/ 0.4 mmNaH2PO4/5.6 mM-glucose/5 mM-Hepes, containing 1 shaken in a water bath at 37 'C. Staurosporine was added from stock solutions in dimethyl sulphoxide to yield a final dimethyl sulphoxide concentration of 0.1 %, which did not change the pattern of phosphorylation in the renatured kinases.
PAGE
Samples were taken at fixed times and solubilized immediately in SDS/PAGE sample buffer, which contained 2.3 % SDS, 0.1, % dithiothreitol, 0.1 mM-EDTA, 62.5 mM-Tris, 10% glycerol, pH 6.8, then vortex-mixed and boiled for 2 min. The samples were separated by electrophoresis in 7.5 %-polyacrylamide gels [29] in a mini-gel system with 30 ug of platelet protein loaded per lane.
Renaturation procedure
Proteins were transferred to PVDF membranes by semi-dry blotting using 0.3 M-Tris/20 % ethanol, pH 10.4, as anode buffer I, 25 mM-Tris/20 % ethanol, pH 10.4, as anode buffer II, and 40 mM-e-aminohexanoic acid, pH 9.4, as cathode buffer with 160 mA constant current for I h. The blots were then immersed for 1 h at room temperature in 7 M-guanidine hydrochloride/SO mM-Tris/50 mM-dithiothreitol/2 mM-EDTA,pH 8.3. The renaturation was performed as described by Ferrell & Martin [28] in 100 mM-NaCI/50 mM-Tris/2 mM-dithiothreitol/ 2 mM-EDTA/0.l % Nonidet P-40/1 % BSA, pH 7.5, at 4°C for 14-16 h with gentle rocking. The membranes were blocked with 30 mM-Tris/3 % BSA, pH 7.5, at room temperature for 1 h.
Kinase reactions were performed by immersing the blocked blots in 30 mM-Tris/10 mM-MgCl2/2 mM-MnCl2, pH 7.5, containing 50 uCi of [y-32P]ATP/ml for 30 min at room temperature. The reaction was stopped by transferring the blots to 30 mM-Tris, pH 7.5. The blots were then washed three times with 30 mM-Tris, pH 7.5, and twice with 30 mM-Tris/0.05 % Nonidet P-40, pH 7.5, followed by treatment with 1 M-KOH for 10 min at room temperature, rinsing several times with water and 100% acetic acid, and drying. Autoradiograms were made with the dried blots from the same experiment together on the same film. The film was photographed, and Fig. 1 After blocking with BSA, the sections were equilibrated with 30 mM-Tris/10 mM-MgCl2/2 mM-MnCl2, pH 5.0, or pH 7.5 for the control. The pH 5.0 sections were then incubated for 10 min with 10 units of acid phosphatase/ml. The reaction was stopped by rinsing several times with the pH 7.5 buffer. The sections were then incubated with the [y-32P]ATP solution as above.
RESULTS AND DISCUSSION
In order to investigate the effect of staurosporine on renaturable protein kinases probably involved in signal transduction, washed human platelets were activated with thrombin and treated with different amounts of the inhibitor. After blocking with BSA, the renatured proteins on the blots were overlaid with [y-32P]ATP. Labelling of the bands agreed well with that previously reported, and the same nomenclature is used [28] . The effects of staurosporine on the activities of the renatured protein kinases were investigated (Fig. 1) . To our surprise, although the activities in vitro of the renaturated protein kinases from platelets treated with staurosporine were expected to decrease, some increased. Treatment of platelets with staurosporine (1 J#M) increased the activity of three protein kinases (Fig.   la) . Staurosporine increased PK 60 (protein kinase of 60 kDa) activity strongly, whereas the increase in PK 170 activity was not
Vol. 275 as intense as that obtained with thrombin. The activity of PK 52 reached a peak very quickly at 20 s, and then decreased slowly. In some experiments staurosporine depressed the activity of PK 56 below the control level. These effects were still detectable but weaker with 0.1 ,tM-staurosporine and disappeared at concentrations of 0.01 JIM and less. When staurosporine (1 ,pM) was added together with thrombin (1 unit/ml), the kinase activities of PK 52, PK 60, PK 150 and PK 170 increased (Fig. lb) . The increases in these activities no longer correlated with the time course of the thrombin-induced increases, especially for PK 60, where the maximum was reached only at 5 min after the addition (Fig. 2) . The increased activities of PK 56 and also of PK 64 after thrombin stimulation were inhibited by staurosporine, although a direct measurement of the radioactivity (c.p.m.) incorporated into PK 64 on the blots was not possible.
To investigate whether staurosporine acts directly on the protein kinases, PVDF membranes were treated with staurosporine in vitro after renaturation and before the incubation with labelled ATP. The activity of almost all the kinases was completely blocked by staurosporine at 10 /tm, except for a very weak remnant activity of PK 52, PK 60 and PK 170 (Fig. 3) . With lower concentrations (0.01 JiM) the inhibition of these kinases was weaker, and the increase in activity of PK 52, PK 56, PK 60 and PK 170 with the thrombin-treated platelets compared with the control re-appeared. Staurosporine may affect the kinases ;36_
In vitro 10-6 10-7 10-8 from control and thrombin-treated platelets differently, since the relatively higher intensities found with the latter disappear with increasing staurosporine concentrations. The group of protein kinases between 80 and 100 kDa (PK 82, PK 86, PK 94) was still completely inhibited at 0.01 uM-staurosporine, although after renaturation they seemed to have been unaffected by staurosporine treatment of intact platelets (Fig. 1) . These three kinases have masses similar to those of PKC (80 kDa) [30] . However, the way in which PKC is activated suggests that it is not detected in this assay system, as it requires at least phosphatidylserine and DAG for activation [31] . The inconsistent weak activity changes after thrombin stimulation also argue against the involvement of the kinases detected in this position in signal transduction. In addition, purified PKC from platelets could not be detected in the kinase assay after SDS/PAGE, Western blotting and renaturation (results not shown).
Phosphorylations of proteins such as pleckstrin that increase during platelet activation are inhibited by staurosporine [24] . In addition, staurosporine also depresses the level of phosphorylation of several phosphoproteins in resting platelets compared with control values (V. von Tscharner & K. J. Clemetson, unpublished work). Interaction with the catalytic subunit of the protein kinases, probably by blocking the ATP-binding site, are responsible for the inhibition [11] . The direct effect of staurosporine is due to non-covalent interaction with the enzymes, and activity is restored after renaturation (Fig. 3) . As staurosporine inhibits all the detected protein kinases in vitro, it probably has the same effect in intact platelets.
Treatment of the renaturated proteins on the blocked blots with acidic phosphatase to create newly vacant phosphorylation sites before treatment with [y-32P]ATP did not result in increased labelling of bands (Fig. 4) . The same was found with alkaline phosphatase (results not shown). The slight overall decrease in activity might be due to hydrolysis of ATP by a small remnant of phosphatase that bound to the membrane. A specific and marked decrease in the activity of PK 170, PK 150 and PK 60 was found that must be due to the direct action of the acid phosphatase on the proteins. This suggests an inactivation of these protein kinases by dephosphorylation in vitro. With alkaline phosphatase the specific decreases in the activities of PK 170 and PK 150 were not found, and the decrease in PK 60 was not so pronounced. These results show that non-specific dephosphorylation of the renaturated proteins on the blots does not increase the apparent activity of the protein kinases by providing free sites for phosphorylation. This suggests an increase in the specific activity of the renaturated protein kinases. The activity towards exogenous substrates (e.g. BSA) is increased by staurosporine in the same way as by thrombin. The pattern (SDS/PAGE) of phosphoproteins in the bands from renaturated blots treated with [y-32P]ATP from staurosporine-or thrombin-treated platelets was conserved (result not shown). Changes in the activity of the protein kinases are most probably due to covalent modifications, as they are conserved after denaturation and renaturation. [3] . As this kinase is not activated by staurosporine alone, and the transient increase of activity that reaches a peak after I min of thrombin treatment (Fig. 2) [18] [19] [20] [21] [22] [23] . In vitro, staurosporine induced the association of purified PKC with inside-out vesicles from erythrocyte membranes in a concentration-dependent manner [32] , suggesting that phorbol 12-myristate 13-acetate and staurosporine act similarly, but, in addition, phosphorylation was inhibited. In the present study we give evidence that staurosporine affects a set of renaturable protein kinases in intact human platelets, leading to activation of three of them (PK 52, PK 60 and PK 170) and inhibiting the activation of one (PK 56). In contrast, it inhibited all the detectable serine/threonine kinases in platelets in vitro in a concentration-dependent manner. This shows that staurosporine, as well as inhibiting kinases directly, can also cause increased platelet responses. As long as no protein kinase is found which is unaffected or even stimulated directly in vitro by staurosporine, this method distinguishes between two general ways of protein kinase control. PK 52 and PK 64 are probably activated by phosphorylation. PK 52 may be activated by another mechanism, including dephosphorylation. As phosphatase treatment in vitro decreased the activities of PK 60, PK 150 and PK 170 (Fig. 4) , activation by another mechanism that is not dephosphorylation can be proposed. 
